Tags

Type your tag names separated by a space and hit enter

Incremental cholecalciferol supplementation up to 15 μg/d throughout winter at 51-55° N has no effect on biomarkers of cardiovascular risk in healthy young and older adults.
J Nutr. 2012 Aug; 142(8):1519-25.JN

Abstract

Two separate, identical, double-blind, randomized, placebo-controlled intervention studies were carried out in the south and north of Ireland (51-55°N). Men and women aged 20-40 y (n = 202) and ≥64 y (n = 192) received cholecalciferol at doses of 0 (P), 5 (D3-5), 10 (D3-10), or 15 (D3-15) μg/d (0-600 IU) during wintertime. Serum 25-hydroxyvitamin D [s25(OH)D], intact parathyroid hormone, systolic and diastolic blood pressure, fasting lipids, glucose and insulin, HOMA-IR, high-sensitivity CRP, matrix metalloproteinase-9, and its inhibitor (tissue inhibitor metalloproteinase-1) were measured at baseline (October) and 22 wk later at endpoint (March). Vitamin D receptor Fok I and Taq I genotypes were analyzed and dietary intakes of vitamin D and calcium were assessed. In young adults, s25(OH)D decreased from baseline to endpoint (P < 0.001), except in the D3-15 group, who maintained the baseline concentration of ~70 nmol/L. Older adults had lower s25(OH)D at baseline (median, 54.2 nmol/L) and concentrations increased in the D3-10 and D3-15 groups (P < 0.001). There were no significant effects of supplementation on cardiovascular disease (CVD) risk biomarkers in either age group. Fasting glucose and total and HDL cholesterol were lower (P < 0.05) in older adults with the Fok 1 ff genotype than in those with FF or Ff. Putative effects of vitamin D on cardio-metabolic health will only be evident at higher intakes than the current RDA and possibly in individuals at particular risk of low s25(OH)D and/or CVD risk.

Authors+Show Affiliations

Vitamin D Research Group, School of Food and Nutritional Sciences, University College, Cork, Ireland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22739371

Citation

Muldowney, Siobhan, et al. "Incremental Cholecalciferol Supplementation Up to 15 Μg/d Throughout Winter at 51-55° N Has No Effect On Biomarkers of Cardiovascular Risk in Healthy Young and Older Adults." The Journal of Nutrition, vol. 142, no. 8, 2012, pp. 1519-25.
Muldowney S, Lucey AJ, Hill TR, et al. Incremental cholecalciferol supplementation up to 15 μg/d throughout winter at 51-55° N has no effect on biomarkers of cardiovascular risk in healthy young and older adults. J Nutr. 2012;142(8):1519-25.
Muldowney, S., Lucey, A. J., Hill, T. R., Seamans, K. M., Taylor, N., Wallace, J. M., Horigan, G., Barnes, M. S., Bonham, M. P., Duffy, E. M., Strain, J. J., Cashman, K. D., & Kiely, M. (2012). Incremental cholecalciferol supplementation up to 15 μg/d throughout winter at 51-55° N has no effect on biomarkers of cardiovascular risk in healthy young and older adults. The Journal of Nutrition, 142(8), 1519-25. https://doi.org/10.3945/jn.111.154005
Muldowney S, et al. Incremental Cholecalciferol Supplementation Up to 15 Μg/d Throughout Winter at 51-55° N Has No Effect On Biomarkers of Cardiovascular Risk in Healthy Young and Older Adults. J Nutr. 2012;142(8):1519-25. PubMed PMID: 22739371.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Incremental cholecalciferol supplementation up to 15 μg/d throughout winter at 51-55° N has no effect on biomarkers of cardiovascular risk in healthy young and older adults. AU - Muldowney,Siobhan, AU - Lucey,Alice J, AU - Hill,Tom R, AU - Seamans,Kelly M, AU - Taylor,Nicola, AU - Wallace,Julie M W, AU - Horigan,Geraldine, AU - Barnes,Maria S, AU - Bonham,Maxine P, AU - Duffy,Emeir M, AU - Strain,J J, AU - Cashman,Kevin D, AU - Kiely,Mairead, Y1 - 2012/06/27/ PY - 2012/6/29/entrez PY - 2012/6/29/pubmed PY - 2012/10/12/medline SP - 1519 EP - 25 JF - The Journal of nutrition JO - J Nutr VL - 142 IS - 8 N2 - Two separate, identical, double-blind, randomized, placebo-controlled intervention studies were carried out in the south and north of Ireland (51-55°N). Men and women aged 20-40 y (n = 202) and ≥64 y (n = 192) received cholecalciferol at doses of 0 (P), 5 (D3-5), 10 (D3-10), or 15 (D3-15) μg/d (0-600 IU) during wintertime. Serum 25-hydroxyvitamin D [s25(OH)D], intact parathyroid hormone, systolic and diastolic blood pressure, fasting lipids, glucose and insulin, HOMA-IR, high-sensitivity CRP, matrix metalloproteinase-9, and its inhibitor (tissue inhibitor metalloproteinase-1) were measured at baseline (October) and 22 wk later at endpoint (March). Vitamin D receptor Fok I and Taq I genotypes were analyzed and dietary intakes of vitamin D and calcium were assessed. In young adults, s25(OH)D decreased from baseline to endpoint (P < 0.001), except in the D3-15 group, who maintained the baseline concentration of ~70 nmol/L. Older adults had lower s25(OH)D at baseline (median, 54.2 nmol/L) and concentrations increased in the D3-10 and D3-15 groups (P < 0.001). There were no significant effects of supplementation on cardiovascular disease (CVD) risk biomarkers in either age group. Fasting glucose and total and HDL cholesterol were lower (P < 0.05) in older adults with the Fok 1 ff genotype than in those with FF or Ff. Putative effects of vitamin D on cardio-metabolic health will only be evident at higher intakes than the current RDA and possibly in individuals at particular risk of low s25(OH)D and/or CVD risk. SN - 1541-6100 UR - https://www.unboundmedicine.com/medline/citation/22739371/Incremental_cholecalciferol_supplementation_up_to_15_μg/d_throughout_winter_at_51_55°_N_has_no_effect_on_biomarkers_of_cardiovascular_risk_in_healthy_young_and_older_adults_ L2 - https://academic.oup.com/jn/article-lookup/doi/10.3945/jn.111.154005 DB - PRIME DP - Unbound Medicine ER -